Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
2.
BMC Infect Dis ; 17(1): 147, 2017 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-28201995

RESUMEN

BACKGROUND: Streptococcus equi subsp. zooepidemicus is a beta-hemolytic group C streptococcus mainly causing infections in domesticated animals. Here we describe the first case of zoonotic necrotizing myositis caused by this bacterium. CASE PRESENTATION: The patient was a 73-year-old, previously healthy farmer with two asymptomatic Shetland ponies in his stable. After close contact with the ponies while feeding them, he rapidly developed erythema of his left thigh and sepsis with multiple organ failure. The clinical course was severe and complicated, requiring repetitive surgical excision of necrotic muscle, treatment with vasopressors, mechanical ventilation and continuous venovenous hemofiltration, along with adjunctive hyperbaric oxygen therapy. The patient was discharged from hospital at day 30, without obvious sequelae. The streptococcal isolate was identified as Streptococcus equi by MALDI-ToF MS, and was later assigned subspecies identification as S. equi subsp. zooepidemicus. Multilocus sequence typing identified the strain as a novel sequence type (ST 364), closely related to types previously identified in horses and cattle. A focused proteomic analysis revealed that the ST 364 expressed putative virulence factors similar to that of Streptococcus pyogenes, including homologues of the M protein, streptodornases, interleukin 8-protease and proteins involved in the biosynthesis of streptolysin S. CONCLUSION: This case illustrates the zoonotic potential of S. equi subsp. zooepidemicus and the importance of early clinical recognition, rapid and radical surgical therapy, appropriate antibiotics and adequate supportive measures when necrotizing soft tissue infection is suspected. The expression of Streptococcus pyogenes-like putative virulence determinants in ST 364 might partially explain the fulminant clinical picture.


Asunto(s)
Dermatomiositis/microbiología , Fascitis Necrotizante/microbiología , Enfermedades de los Caballos/microbiología , Insuficiencia Multiorgánica/microbiología , Infecciones Estreptocócicas/microbiología , Streptococcus equi/patogenicidad , Anciano , Crianza de Animales Domésticos , Animales , Dermatomiositis/inmunología , Dermatomiositis/terapia , Agricultores , Fascitis Necrotizante/terapia , Hemofiltración , Enfermedades de los Caballos/inmunología , Caballos , Humanos , Oxigenoterapia Hiperbárica , Masculino , Tipificación de Secuencias Multilocus , Insuficiencia Multiorgánica/terapia , Infecciones Estreptocócicas/terapia , Infecciones Estreptocócicas/veterinaria , Streptococcus equi/inmunología , Resultado del Tratamiento , Vasoconstrictores/uso terapéutico , Zoonosis
3.
Shock ; 44(4): 357-64, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26125086

RESUMEN

Endostatin is an endogenous inhibitor of vascular endothelium. It can inhibit endothelial cell migration, proliferation, and vascular angiogenesis and is mainly used for anticancer therapy. We have previously found that endostatin is an important node protein in the pathogenesis of sepsis. However, its impacts on sepsis have not yet been reported. We established a septic mouse model using cecal ligation and puncture (CLP) and gave the mice either endostatin or placebo (saline). The effects of endostatin on serum enzyme, Evans blue leakage, lung wet-to-dry weight ratio, and cytokine (tumor necrosis factor α, interleukin 1ß [IL-1ß], and IL-6) production were assessed. Survival rates were observed for up to 3 days. In addition, we examined the effects of endostatin on serum vascular endothelial growth factor A (VEGF-A), VEGF-C, and pathological changes and scores of lung tissues as well as the phosphorylation of JNK, p38, and ERKl/2 proteins in lung tissues of mice with sepsis. We found that endostatin can increase the survival of septic mice in a time- and dose-dependent manner probably by reducing multiorgan dysfunctions shown by serum indicators, morphologic changes, Evans blue leakage, wet-to-dry weight ratio, and inflammation of lung tissues. In addition, endostatin could reduce serum tumor necrosis factor α, IL-1ß, IL-6, and VEGF-C levels in septic mice as well as inhibit phosphorylation of p38 and ERK1/2 in lung tissues of septic mice. This is the first study demonstrating the protective effect of endostatin on sepsis and its possible underlying mechanisms from the aspects of inhibiting inflammatory responses, blocking VEGF receptor, attenuating VEGF-C expression, and reducing vascular permeability. Overall, the study revealed the potential protect role for endostatin in the treatment of sepsis.


Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Endostatinas/uso terapéutico , Insuficiencia Multiorgánica/prevención & control , Sepsis/complicaciones , Inhibidores de la Angiogénesis/administración & dosificación , Animales , Citocinas/biosíntesis , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Endostatinas/administración & dosificación , Mediadores de Inflamación/sangre , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Masculino , Ratones , Insuficiencia Multiorgánica/metabolismo , Insuficiencia Multiorgánica/microbiología , Sepsis/metabolismo , Análisis de Supervivencia , Factor A de Crecimiento Endotelial Vascular/sangre
4.
Asian Pac J Trop Med ; 6(11): 889-92, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24083585

RESUMEN

OBJECTIVE: To analyze the effect of intestinal function-recovering decoction on multiple organ dysfunction syndrome in rats, and to investigate a novel solution to multiple organ dysfunction syndrome. METHODS: Multiple organ dysfunction syndrome was induced in 60 Sprague-Dawley rats by intestinal ischemia-reperfusion combined with cecal ligation and puncture. Then these rats were intragastrically administered physiological saline (group I, n=20), ampicillin (group II, n=20) or intestinal function-recovering decoction (group III, n=20). After treatment, serum malondialdehyde and superoxide dismutase levels were compared among three groups. Simultaneously, bacterial culture of various organ tissues was performed and bacterial and endotoxin translocation were observed. RESULTS: Compared with group I, serum malondialdehyde, alanine aminotransferase and aspartate aminotransferase levels were significantly decreased (all P<0.05) and serum superoxide dismutase level was significantly increased (P<0.05) in the group III. However, there were no significant differences in these indices between groups II and III (P>0.05). The rate of bacterial translocation in the groups II and III was significantly lower than in the group I (P<0.05), and no significant difference was observed between groups II and III (P>0.05). CONCLUSIONS: Intestinal function-recovering decoction can significantly reduce endotoxin and bacterial translocation and stabilize enteral oxidative-antioxidative balance.


Asunto(s)
Ampicilina/farmacología , Antibacterianos/farmacología , Medicamentos Herbarios Chinos/farmacología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/fisiopatología , Insuficiencia Multiorgánica/tratamiento farmacológico , Insuficiencia Multiorgánica/fisiopatología , Animales , Traslocación Bacteriana , Modelos Animales de Enfermedad , Endotoxinas/sangre , Femenino , Mucosa Intestinal/microbiología , Masculino , Malondialdehído/sangre , Insuficiencia Multiorgánica/microbiología , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/sangre
5.
Food Chem Toxicol ; 47(6): 1341-8, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19298839

RESUMEN

Sepsis is an acute life-threatening clinical condition and remains the major cause of death in intensive care units. The primary pathophysiologic event central to the septic response is an overwhelming activation of the inflammatory system and countervailing response from the anti-inflammatory system. However, the cause of this perturbation has yet to be elucidated. In this study, we report that Aloe vera therapeutically reverses the lethality induced by cecal ligation and puncture (CLP), a clinically relevant model of sepsis. The administration of Aloe vera ameliorated the multiple organ dysfunction syndrome, as evidenced by the serum levels of biochemical parameters and histological changes. In order to investigate the pharmacological mechanism of Aloe vera, the levels of the cytokines, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 were determined by ELISA at various time points. The increases in the levels of TNF-alpha, IL-1beta, and IL-6 were attenuated by Aloe vera.In vivo administration of Aloe vera also markedly enhanced bacterial clearance. Our findings suggest that Aloe vera could be a potential therapeutic agent for the clinical treatment of sepsis.


Asunto(s)
Aloe/química , Fitoterapia , Sepsis/microbiología , Sepsis/prevención & control , Animales , Líquido Ascítico/microbiología , Nitrógeno de la Urea Sanguínea , Ciego/microbiología , Recuento de Colonia Microbiana , Citocinas/biosíntesis , Ensayo de Inmunoadsorción Enzimática , Pruebas de Función Cardíaca , Inflamación/patología , Interleucina-1beta/sangre , Pruebas de Función Renal , Pruebas de Función Hepática , Masculino , Ratones , Ratones Endogámicos ICR , Insuficiencia Multiorgánica/microbiología , Insuficiencia Multiorgánica/patología , Sepsis/patología , Análisis de Supervivencia , Factor de Necrosis Tumoral alfa/sangre
6.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 26(3): 277-80, 2006 Mar.
Artículo en Chino | MEDLINE | ID: mdl-16613280

RESUMEN

Bacteria translocation (BT) induced enterogenous infection in multiple organs dysfunction syndrome (MODS) is closely related with the stress pyemia and MODS. For prevention of BT, western medicine stresses to improve the blood and oxygen supply of intestinal tract, mucosa protection, and application of microorganism preparation, while traditional Chinese medicine could also win good effect by using such drugs as rhubarb, red sage root, and compound decoctions.


Asunto(s)
Traslocación Bacteriana/efectos de los fármacos , Medicamentos Herbarios Chinos/uso terapéutico , Insuficiencia Multiorgánica/microbiología , Fitoterapia , Animales , Humanos , Mucosa Intestinal/fisiopatología
7.
Surg Today ; 35(2): 126-30, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15674493

RESUMEN

PURPOSE: To select the most appropriate antibiotic regimens for life-threatening postoperative infections, we obtained isolates from patients with severe postoperative infections over a 12-year-period, and examined their drug susceptibility. METHODS: The subjects of this study were 55 patients with multiple organ failure (MOF) caused by postoperative infection. RESULTS: All strains of Methicillin-resistant Staphylococcus aureus (MRSA) were susceptible to Vancomycin (VCM) and Teicoplanin (TEIC). Only 0.3% of all the Pseudomonas aeruginosa strains were resistant to Imipenem (IPM), but 53.6% of the strains from the severe infections were resistant to IPM. On the other hand, there were few P. aeruginosa strains resistant to Meropenem (MEPM), Ceftazidime (CAZ), Ciprofloxacin (CPFX), and Pazufloxacin (PZFX), even among strains isolated from severe infections. The resistant rate of Bacteroides fragilis to Clindamycin (CLDM) was 35.9%, but there were strains resistant to IPM and Panipenem. CONCLUSION: These findings suggest that VCM or TEIC are most appropriate for severe abdominal abscess caused by MRSA, whereas MEPM, CAZ, CPFX, and PZFX are more effective against P. aeruginosa infections. The only antibiotic effective against B. fragilis infections in this study was IPM.


Asunto(s)
Absceso Abdominal/microbiología , Quimioterapia Combinada/uso terapéutico , Insuficiencia Multiorgánica/microbiología , Complicaciones Posoperatorias/microbiología , Absceso Abdominal/tratamiento farmacológico , Antibacterianos/uso terapéutico , Infecciones por Bacteroides/tratamiento farmacológico , Bacteroides fragilis/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Complicaciones Posoperatorias/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Infecciones Estafilocócicas/tratamiento farmacológico
8.
Voen Med Zh ; 325(2): 33-9, 96, 2004 Feb.
Artículo en Ruso | MEDLINE | ID: mdl-15101292

RESUMEN

The experience of optimization of empirical antibacterial therapy of diffuse purulent peritonitis at toxic and terminal stages is presented. The treatment results were compared in main (209) and control (130) patient groups taking into account the clinical and bacteriological efficiency. The technology of combined antibacterial multi-component retroperitoneal lymphotropic therapy was used that included the following drugs: novocain, haemodesum, trisaminum, hydrocortison hemisuccinas, heparin, tripsinum and antibacterial group (kanamicini, levomycetinum, natrii hemisuccinas, dioxydinum, metronidazole) for abdominal and retroperitoneal treatment. 96.7% from the main group and 74.6% from the control group recovered, lethal outcomes and complications decreased in 2.78 and 4 times respectively.


Asunto(s)
Antibacterianos/uso terapéutico , Insuficiencia Multiorgánica/tratamiento farmacológico , Peritonitis/tratamiento farmacológico , Antibacterianos/administración & dosificación , Farmacorresistencia Bacteriana/efectos de los fármacos , Quimioterapia Combinada , Humanos , Pruebas de Sensibilidad Microbiana , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/microbiología , Peritonitis/complicaciones , Peritonitis/microbiología , Índice de Severidad de la Enfermedad , Supuración , Resultado del Tratamiento
9.
Rev Med Interne ; 24(5): 295-304, 2003 May.
Artículo en Francés | MEDLINE | ID: mdl-12763175

RESUMEN

OBJECTIVE: To present and discuss the rationale and the results of clinical trials using supplementation with physiologic anticoagulants (Tissue Factor Pathway Inhibitor (TFPI), AntiThrombin (AT), and Protein C (PC) in patients with severe sepsis. RATIONALE: An early activation of the coagulation cascade occurs in severe sepsis. TFPI, AT, and PC are major inhibitors of the coagulation cascade, and additionally modulate inflammatory and vascular reactions. They are consumed or inhibited in the sepsis pathologic process. Therapeutic supplementation with these inhibitors could improve the sepsis-induced organ failures and mortality. CLINICAL RESULTS: Randomized controlled studies were recently completed. No effect on the mortality rate could be documented after treatment with recombinant TFPI. AT concentrates neither improve mortality, but a biological interaction with heparin therapy could have biased the study results. Treatment with recombinant activated PC (alpha-drotrecogin) was associated with a significant reduction in the mortality rate of severely ill patients and received recently the approval from FDA and EC authorities in this indication. An increase in the rate of hemorrhagic adverse effects has been observed with these compounds, justifying a strict observance of contraindications and of patients selection. PROSPECTIVE: Additional studies are needed to give confirmation of the positive effects of activated PC supplementation in less severely ill patients, children and specific clinical situations. The effects of new anticoagulant compounds are currently evaluated in preclinical studies.


Asunto(s)
Anticoagulantes/uso terapéutico , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/microbiología , Sepsis/complicaciones , Anticoagulantes/farmacología , Antitrombinas/efectos de los fármacos , Antitrombinas/fisiología , Trastornos de la Coagulación Sanguínea/mortalidad , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Monitoreo de Drogas , Heparina/uso terapéutico , Humanos , Inflamación , Insuficiencia Multiorgánica/microbiología , Selección de Paciente , Proteína C/antagonistas & inhibidores , Proteína C/fisiología , Proteína C/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Proteínas Recombinantes/uso terapéutico , Sepsis/sangre , Sepsis/inmunología , Índice de Severidad de la Enfermedad , Tromboplastina/antagonistas & inhibidores , Tromboplastina/efectos de los fármacos , Tromboplastina/fisiología , Resultado del Tratamiento
10.
Am J Surg ; 179(5): 361-6, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10930480

RESUMEN

OBJECTIVE: A large number of necrotizing soft tissue infections (NSTI) treated at a single institution over an 8-year period were analyzed with respect to microbial pathogens recovered, treatment administered, and outcome. Based on this analysis, optimal empiric antibiotic coverage is proposed. METHODS: A retrospective chart review of all patients with documented NSTI was conducted. Microbiologic variables were tested for impact on outcome using Fisher's exact test and multivariate analysis by logistic regression. RESULTS: Review of the charts of 198 patients with documented NSTI revealed 182 patients with sufficient microbiologic information for analysis. These 182 patients grew an average of 4.4 microbes from original wound cultures, although a single pathogen was responsible in 28 patients. Eighty-five patients had combined aerobic and anaerobic growth, the most common organisms being, in order, Bacteroides species, aerobic streptococci, staphylococci, enterococci, Escherichia coli, and other gram-negative rods. Clostridial growth was common but did not affect mortality unless associated with pure clostridial myonecrosis. Mortality was affected by the presence of bacteremia, delayed or inadequate surgery, and degree of organ system dysfunction on admission. CONCLUSIONS: NSTI are frequently polymicrobial and initial antibiotic coverage with a broad-spectrum regimen is warranted. The initial regimen should include agents effective against aerobic gram-positive cocci, gram-negative rods, and a variety of anaerobes. The most common organisms not covered by initial therapy were enterococci. All wounds should be cultured at initial debridement, as changes in antibiotic coverage are frequent once isolates are recovered.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/terapia , Desbridamiento , Fascitis Necrotizante/microbiología , Fascitis Necrotizante/terapia , Micosis/microbiología , Micosis/terapia , Infecciones de los Tejidos Blandos/microbiología , Infecciones de los Tejidos Blandos/terapia , Algoritmos , Bacteriemia/microbiología , Infecciones Bacterianas/mortalidad , Infecciones Bacterianas/patología , Terapia Combinada , Fascitis Necrotizante/mortalidad , Fascitis Necrotizante/patología , Humanos , Modelos Logísticos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Insuficiencia Multiorgánica/microbiología , Análisis Multivariante , Micosis/mortalidad , Micosis/patología , Necrosis , Estudios Retrospectivos , Infecciones de los Tejidos Blandos/mortalidad , Infecciones de los Tejidos Blandos/patología , Análisis de Supervivencia , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA